Concepedia

Mark W. Ledeboer

MW

Statistics

Publications

19

Citations

1.2K

H-Index

19

Active since

1996

Affiliations

Vertex Pharmaceuticals (United States)(Current)

Goldfinch Bio (United States)

Scripps Research Institute

Vertex Pharmaceuticals (Canada)

Mark W. Ledeboer is an author at Vertex Pharmaceuticals (United States) specializing in medicinal chemistry, pharmacology, and drug discovery.

ORCID

Publications per year

1996–2022

19

Publications

19

Discovery of a Novel, First-in-Class, Orally Bioavailable Azaindole Inhibitor (VX-787) of Influenza PB2

Michael P. Clark, Mark W. Ledeboer, Ioana Davies et al. · Journal of Medicinal Chemistry · 2014 · 211 citations · Full text

, , +17

Preclinical Activity of VX-787, a First-in-Class, Orally Bioavailable Inhibitor of the Influenza Virus Polymerase PB2 Subunit

Randal A. Byrn, Hamilton B. Bennett, Chris Bral et al. · Antimicrobial Agents and Chemotherapy · 2014 · 188 citations · Full text

, , +17

Asymmetric Reduction. A Convenient Method for the Reduction of Alkynyl Ketones

Kathlyn A. Parker, Mark W. Ledeboer · The Journal of Organic Chemistry · 1996 · 119 citations

, , +6

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases

Luc J. Farmer, Mark W. Ledeboer, Thomas Hoock et al. · Journal of Medicinal Chemistry · 2015 · 89 citations

, , +13

Structural basis of TRPC4 regulation by calmodulin and pharmacological agents

Deivanayagabarathy Vinayagam, Dennis Quentin, Jing Yu-Strzelczyk et al. · eLife · 2020 · 70 citations · Full text

, , +17

1–5 of 19